FDA Releases Final Guidance on Adaptive Designs for Clinical Trials of Drugs and Biologics

Summary

The Food and Drug Administration (FDA) has released a final guidance for industry on the use of adaptive designs in clinical trials for drugs and biologics, providing guidance for sponsors and applicants on the appropriate use of these designs to demonstrate effectiveness and safety.